A股異動 | 康泰生物升近6% 與印尼Biotis公司簽署合作協議
格隆匯4月7日丨康泰生物(300601.SZ)升近5.9%,報33.76元,總市值377億元。4月5日上午,深圳康泰生物製品股份有限公司全資子公司民海生物與印尼Biotis公司在北京舉行簽約儀式,在印尼衞生部副部長丹特·薩克索諾、印尼駐華大使周浩黎、中華國際醫學交流基金會理事長劉雁飛、中國醫藥保健品進出口商會會長周惠等嘉賓的共同見證下,雙方簽署了雙載體13價肺炎球菌多糖結合疫苗的授權及技術轉移協議。根據協議內容,民海生物將向Biotis供應雙載體13價肺炎疫苗原液,並針對疫苗的配製、分裝、成品檢定等技術進行轉移;後續雙方將共同推進雙載體13價肺炎疫苗在印尼的本地化生產、註冊、商業化運營等進程。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.